* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Understanding Multiple Sclerosis, symptoms
Survey
Document related concepts
Ulcerative colitis wikipedia , lookup
Globalization and disease wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
Common cold wikipedia , lookup
Behçet's disease wikipedia , lookup
Rheumatoid arthritis wikipedia , lookup
Autoimmune encephalitis wikipedia , lookup
Myasthenia gravis wikipedia , lookup
Signs and symptoms of Graves' disease wikipedia , lookup
Neuromyelitis optica wikipedia , lookup
Pathophysiology of multiple sclerosis wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Transcript
Name of Disorder: Multiple Sclerosis Essay Title: Understanding Multiple Sclerosis, symptoms, diagnosis and treatment Author: Dr Lucy Vivash, MSci, PhD (medicine) Institution: Melbourne Brain Centre, Royal Melbourne Hospital Date: 13th June 2014 Multiple sclerosis (MS) is a common neurological disease which affects approximately 23,000 Australians, and 2-2.5 million people worldwide. The geographical distribution of MS is variable, being more common in regions that are farther from the equator. MS is typically diagnosed aged 20-50 years, and is also known to affect twice as many women as men, however, the reason for this is unclear. MS is considered an autoimmune disease, meaning the immune system, which normally protects the body from infection causing agents including viruses and bacteria, mistakenly attacks the body’s own cells and tissues. Specifically in MS, the immune cells attack myelin, the insulating cells that surround the nerves in the brain and spine. This attack on myelin slows the transmission of messages from the brain to the body, resulting in the symptoms observed in patients with MS. Symptoms The symptoms of MS vary greatly between patients. The most common symptoms are changes to sensation (tingling, pins and needles, numbness), muscle weakness and spasms, difficulty in movement, coordination and balance, speech difficulties, vision problems (blurring and double vision), tiredness, pain and urinary incontinence. In the early stages of the disease symptoms are mild. As the disease progresses patients will exhibit a greater number and severity of symptoms. There are currently four/five subtypes of MS, which have differing manifestations. These are: Relapsing-remitting MS – Symptoms are present for a period of time (a relapse) which is followed by a (partial) resolution of symptoms (the remission period). As the disease progresses period of relapse increase in duration and severity and periods of remission occur less frequently. Secondary progressive MS – Relapsing-remitting MS often evolves into secondary progressive MS (approximately 65% of cases). When affected by secondary progressive MS, patients experience symptoms constantly (with a degree of variability of severity still present in some patients). Primary progressive MS – Patients present with symptoms which slowly worsen without any remission periods. Some patients experience a plateauing of their symptoms, whilst in other patients symptoms and disability will continuously evolve over a number of months and years. This affects approximately 10% of patients. Relapsing progressive MS – As with primary progressive MS, symptoms slowly worsen, however in this case there may be one or more relapses that provide some relief to the patients. Diagnosis Diagnosis of MS is based on a patient’s medical history, neurological examination and an MRI of the brain and spinal cord. The McDonald criteria combine clinical presentation and findings from the MRI to diagnose MS, and typically MS is diagnosed after a patient has had one or two relapses, and has an identifiable lesion on MRI. The MRI used for diagnosing MS involves the injection of a contrast agent called gadolinium. The gadolinium enters the brain (and spinal cord) and lights up areas of damage to the myelin. These areas are known as lesions. Patients must have two or more lesions on MRI for a diagnosis of MS. In patients with relapsing-remitting MS, lesions bigger and brighter during a period of relapse, and may not be present during a period of remission. Patients who do not meet all the criteria for a diagnosis of MS may be diagnosed with clinically isolated syndrome (CIS). CIS typically evolves into MS in a large proportion of patients. Treatment Currently there is no cure for MS. There are two types of treatments that are used in the treatment of MS, disease-modifying treatments that modify the immune system and treatments that alleviate the symptoms of MS. Disease-modifying treatments target the immune system. These are primarily used to treat relapsing-remitting MS and include immunotherapies such as interferon beta1a and 1b, glatiramer acetate and fingolimod. These therapies are moderately effective in reducing the number of attacks in patients with relapsing remitting MS. In patients with CIS, treatment with interferons has been shown to reduce the probability that patients will develop clinical MS. Despite the availability of a number of disease-modifying treatments for relapsingremitting MS, there are no approved treatments for primary progressive MS, and only one treatment for secondary progressive MS, mitoxantrone. Mitoxantrone has been shown to slow disease progression, although further evidence is required to confirm this. Significant side effects have been reported in relation to disease-modifying treatments, the most common being irritation around the site of injection. Other side effects include flu-like symptoms, heart palpitations, anxiety, chest tightness, hypertension and bradycardia, which have been reported across a range of diseasemodifying treatments. In cases were disease-modifying treatments are not suitable other treatments are available to reduce and alleviate symptoms of MS. Physiotherapy can aid in reducing muscle stiffness and spasms, as well as incontinence. Muscle spasms may also be reduced by baclofen and zanaflex, with valium helpful in reducing spasms during sleep. Botulinum toxin can also be injected locally to relax muscles. Numerous medications are also available to treat a variety of other symptoms including amantadine for fatigue, anticholinergic drugs to treat incontinence, and anxiolytics and antidepressants to treat anxiety and depression. Neuropsychological and counselling services can also aid in managing stress and providing behavioural therapy to help manage symptoms. Conclusion MS is a chronic, disabling neurodegenerative disease. The majority of patients lead normal lives for many years after their initial diagnosis, with appropriate treatment and engagement with support services. However, the chronic nature of the disease will eventually negatively impact the patients’ life. For this reason a far greater understanding of the underlying biological processes is required to identify new targets for disease-modifying treatments, and to measure the effect of novel treatments on disease progression.